DAKLINZA

This brand name is authorized in Brazil, Estonia, Hong Kong SAR China, Lithuania, Poland, Singapore.

Active ingredients

The drug DAKLINZA contains one active pharmaceutical ingredient (API):

1	Daclatasvir UNII LI2427F9CI - DACLATASVIR
	Daclatasvir is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly.
	Read more about Daclatasvir

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AP07		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AP Antivirals for treatment of HCV infections
Discover more medicines within J05AP07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	505115030021402, 505115030021502, 505115120021702
EE	Ravimiamet	1662601, 1662612, 1722596
HK	Department of Health Drug Office	64505
LT	Valstybinė vaistų kontrolės tarnyba	1074203, 1074204, 1074205, 1074206, 1080851, 1080852
PL	Rejestru Produktów Leczniczych	100323527, 100323533
SG	Health Sciences Authority	14804P, 14805P